Balance of Angiotensin II Receptors in Vessel Function After Preeclampsia
Otherwise healthy women who develop preeclampsia during pregnancy are more likely to develop and die of cardiovascular disease later in life. The reason why this occurs is unclear but may be related to impaired endothelial function and dysregulation of the angiotensin system that occurs during preeclampsia and persists postpartum, despite the remission of clinical symptoms. The purpose of this investigation is to determine the mechanisms contributing to this lasting blood vessel damage caused by reduced endothelial function in women who have had preeclampsia compared to women who had a healthy pregnancy. Identification of these mechanisms and treatment strategies may lead to better clinical management of cardiovascular disease risk in these women. The purpose of this study is to examine differences in the microvascular balance of angiotensin II receptors women who have had preeclampsia. This will help the investigators better understand the mechanisms of dysregulated angiotensin II receptors in formerly preeclamptic women, and how activation or inhibition of these receptors may restore microvascular function. In this study, the investigators use the blood vessels in the skin as a representative vascular bed for examining mechanisms of microvascular dysfunction in humans. Using a minimally invasive technique (intradermal microdialysis for the local delivery of pharmaceutical agents) the investigators examine the blood vessels in a dime-sized area of the skin.
Conditions:
🦠 Preeclampsia
🗓️ Study Start (Actual) 1 December 2023
🗓️ Primary Completion (Estimated) November 2024
✅ Study Completion (Estimated) November 2024
👥 Enrollment (Estimated) 30
🔬 Study Type INTERVENTIONAL
📊 Phase EARLY_PHASE1
Locations:
📍 Iowa City, Iowa, United States

📋 Eligibility Criteria

Description

    Inclusion Criteria:

    • * women who had preeclampsia and women who did not have preeclampsia
    • * 12 weeks to 5 years postpartum
    • * 18-45 years old

    Exclusion Criteria:

    • * history of hypertension or metabolic disease before pregnancy
    • * history of gestational diabetes or gestational hypertension
    • * skin diseases
    • * current tobacco use
    • * current antihypertensive medication
    • * statin or other cholesterol-lowering medication
    • * currently pregnant or planning to become pregnant
    • * body mass index less than \<18.5 or \>30 kg/m2
    • * allergy to materials used during the experiment.(e.g. latex),
    • * known allergy to study drugs
Ages Eligible for Study: 18 Years to 45 Years (ADULT)
Sexes Eligible for Study: FEMALE
Accepts Healthy Volunteers: Yes

🗓️ Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

  • First Submitted 27 November 2023
  • First Submitted that Met QC Criteria 4 December 2023
  • First Posted 6 December 2023

Study Record Updates

  • Last Update Submitted that Met QC Criteria 10 May 2024
  • Last Update Posted 13 May 2024
  • Last Verified May 2024